RD
Publicaties op Oncologisch.com
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AM...
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the U...
FLAG-Ida plus GO bij AML: analyse
Augmented RIC versus standaard RIC voor allo-SCT bij AML: BMT CTN 0901